Research progress on dexmedetomidine-assisted clinical treatment of intracranial aneurysms

Abstract

This study comprehensively analyzes the application and clinical progress of dexmedetomidine in the treatment of intracranial aneurysms. Intracranial aneurysms have become an important challenge in the field of neurosurgery due to their risk of rupture and high mortality rate. In this context, the use of dexmedetomidine is particularly important, especially in perioperative management to maintain hemodynamic stability and provide effective sedation. A review of research shows that dexmedetomidine, due to its α2-adrenoceptor agonist properties, can effectively reduce intraoperative blood pressure and heart rate fluctuations, reduce changes in intracranial pressure, and reduce the risk of aneurysm rupture. Furthermore, it shows potential advantages in reducing postoperative complications and accelerating recovery. However, its suitability in specific patient groups and safety of long-term use still require further study. In the Discussion section, we highlight the advantages of dexmedetomidine, such as stable sedation and subtle effects on the cardiovascular system, while pointing out the limitations and challenges of its use in specific patient populations. Future research should focus on determining the optimal clinical use of dexmedetomidine, including dosage, timing of administration, and suitability for specific patient populations. Taken together, dexmedetomidine has shown obvious advantages in perioperative management of intracranial aneurysm surgery, but its optimal application method and long-term safety still require more clinical research support. This study provides important reference information for future clinical practice and provides a scientific basis for further optimizing treatment strategies for patients with intracranial aneurysms.